-
Anti CD19 car-t cell therapy! Bristol Myers Squibb LISO cel outpatient treatment R / R NHL showed high remission rate (80%) and good safety!
Time of Update: 2019-12-12
December 12, 2019 / BIOON / -- the 61st annual meeting of the American Society of Hematology (ash2019) was recently held in Orlando, Florida, USA At this meeting, BMS published the results of a separa
-
First line treatment does not accord with stem cell transplantation of multiple myeloma! Darzalex + Rd regimen significantly prolonged progression free survival
Time of Update: 2019-12-12
December 12, 2019 / BIOON / -- the 61st annual meeting of the American Society of Hematology (ash2019) was recently held in Orlando, Florida, USA At the meeting, Janssen Pharmaceutical, a subsidiary o
-
Anti CD19 car-t cell therapy! Bristol Myers Squibb LISO cel in the treatment of relapsed / refractory large B cell NHL total remission rate of 100%!
Time of Update: 2019-12-11
December 11, 2019 / BIOON / -- the 61st annual meeting of the American Society of Hematology (ash2019) was recently held in Orlando, Florida, USA At this meeting, BMS released the preliminary data of
-
Double specific cancer immunotherapy! Mosunetuzumab and cd20-tcb showed strong efficacy in the treatment of refractory lymphoma!
Time of Update: 2019-12-10
December 10, 2019 / BIOON / -- the 61st annual meeting of the American Society of Hematology (ash2019) was recently held in Orlando, Florida, USA At the meeting, Roche released new data on two types o
-
Anti CD19 car-t cell therapy! Bristol Myers Squibb LISO cel in the treatment of high-risk relapse / refractory CLL / SLL to achieve rapid MRD negative remission!
Time of Update: 2019-12-10
December 10, 2019 / BIOON / -- the 61st annual meeting of the American Society of Hematology (ash2019) was recently held in Orlando, Florida, USA At this meeting, BMS released the data of phase I / II
-
Domestic target anti-tumor drug LAG-3! China Phase I clinical study of Xinda biological monoclonal antibody ibi110 completed the first case of Drug Administration
Time of Update: 2019-12-07
December 7, 2019 news / BIOON / -- innovent biologics is a biopharmaceutical company dedicated to R & D, production and sales of innovative drugs for the treatment of major diseases such as tumor, aut
-
Immunotherapy for bladder cancer! MSD keytruda treatment NMIBC in the United States into the priority review
Time of Update: 2019-12-07
The US FDA has accepted and granted priority review to a supplementary biologicals licensing application (SBLA) from keytruda, an anti-PD-1 therapy, Merck said recently The SBLA applied for approval o
-
Targeted "high energy" tumor immunotherapy flx475 is expected to benefit specific gastric cancer / lung cancer patients
Time of Update: 2019-12-07
Recently, in 2018, rapid therapeutics (formerly known as FLX bio), a biotech company, announced that it would reach an R & D cooperation of up to $118 million with Hanmi pharmaceutical in South Korea
-
Domestic CD19 car-t cell therapy! Casi / synbiotic cnct19 cell injection was approved by nmpa to carry out new drug clinical trials in China!
Time of Update: 2019-12-06
December 6, 2019 / BIOON / -- CASI pharmaceuticals, Inc is a NASDAQ listed Biomedical Company in the United States It has drug development, product acceleration and innovative therapy exploration plat
-
New choice of first line immunotherapy for non squamous lung cancer! Roche tumor immunotherapy tecentriq + chemotherapy program has been approved by the US FDA!
Time of Update: 2019-12-06
December 6, 2019 / BIOON/ --Roche, a Swiss pharmaceutical giant, recently announced that the U.S Food and Drug Administration (FDA) has approved the first-line treatment of metastatic non squamous non
-
Immunotherapy for NMIBC! Key truda of MSD has entered the priority review in the United States!
Time of Update: 2019-12-04
December 4, 2019 / BIOON / -- cancer immunotherapy giant Merck & Co recently announced that the US FDA has accepted a supplementary biological product license application (SBLA) from keytruda (Chinese
-
Immunotherapy for lung cancer! AstraZeneca imfinzi first-line treatment of extensive small cell lung cancer (SCLC) by the U.S. FDA priority review!
Time of Update: 2019-11-30
November 30, 2019 / BIOON / -- AstraZeneca recently announced that the U.S Food and Drug Administration (FDA) has accepted and granted SBLA for first-line treatment of patients with extensive small ce
-
New drug for neuroblastoma! Y-mabs company's gD2 targeted antibody, naxitamab, has applied for listing in the United States, with a total remission rate of 78% in combination with GM-CSF
Time of Update: 2019-11-30
November 30, 2019 news / BIOON / -- y-mabs is a biopharmaceutical company in the late clinical stage, dedicated to the development and commercialization of new antibody based cancer treatment products
-
Individualized cancer vaccine! Tlpldc, an autotherapy vaccine, has a strong therapeutic effect in the treatment of high-risk melanoma, reducing the risk of recurrence by 50%!
Time of Update: 2019-11-29
November 29, 2009 / BIOON / -- Elios therapeutics is a biopharmaceutical company dedicated to the development of innovative individual therapeutic cancer vaccine Recently, the company published the ma
-
Tumor immunotherapy! Ono has submitted a supplementary application for opdivo in Japan, increasing the dosage plan every four weeks
Time of Update: 2019-11-29
November 28, 2019 / BIOON / -- Ono pharmaceutical recently announced that it has submitted a supplementary application in Japan to change the approved marketing approved part of the production of intr
-
Congratulate! Xinda biology / Lilly innovation PD-1 inhibitor Dabusu (xindilimab injection) is listed in the new national medical insurance catalog!
Time of Update: 2019-11-28
November 28, 2019 news / BIOON / -- innovent biologics is a biopharmaceutical company dedicated to R & D, production and sales of innovative drugs for the treatment of major diseases such as tumor, au
-
Three negative breast cancer first immunization program! Roche launched tecentriq 840mg intravenous preparation in Japan to provide optimized treatment plan!
Time of Update: 2019-11-28
November 28, 2019 / BIOON / -- Chugai Pharma, a Japanese pharmaceutical company controlled by Roche, recently announced the launch of 840mg intravenous preparation of PD-L1 tumor immunotherapy tecentr
-
PD-1 / HER2 bispecific antibody! Xinda biological tumor immunotherapy ibi315 completed the first patient administration in phase I clinical research!
Time of Update: 2019-11-27
November 27, 2019 / BIOON / -- innovent biologics is a biopharmaceutical company dedicated to R & D, production and sales of innovative drugs for the treatment of major diseases such as tumor, autoimm
-
Immunotherapy for lung cancer in China! Keysruda (coreda) was approved for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) combined with chemotherapy!
Time of Update: 2019-11-27
November 27, 2019 / BIOON / -- cancer immunotherapy giant Merck& CO) recently announced that keytruda (Chinese trade name: coreida, common name: pembrolizumab, pabolizumab) has been approved by the Na
-
Ten years of major liver cancer Roche Tecentriq+Avastin combination phase III clinical significantly prolongs overall survival and progression-free survival!
Time of Update: 2019-11-26
November 26, 2019 / BIOON / -- Roche recently announced cancer at the Asia Conference of the European Society of Oncology (ESMO) in Singapore Immunotherapy tecentriq (atezolizumab, anti-PD-L1 antibody
